These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23773943)

  • 1. [Statins after drug discontinuation are usually well tolerated].
    Steurer J
    Praxis (Bern 1994); 2013 Jun; 102(13):813. PubMed ID: 23773943
    [No Abstract]   [Full Text] [Related]  

  • 2. The HMG Co-A reductase inhibitors ('statins') and myotoxic effects.
    S Afr Med J; 2002 Aug; 92(8):596-7. PubMed ID: 12244613
    [No Abstract]   [Full Text] [Related]  

  • 3. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
    Golomb B; Evans M
    Drug Saf; 2006; 29(12):1191; author reply 1191-2. PubMed ID: 17147465
    [No Abstract]   [Full Text] [Related]  

  • 4. Relief of photoallergy: atorvastatin replacing simvastatin.
    Sommer M; Trautmann A; Stoevesandt J
    J Investig Allergol Clin Immunol; 2015; 25(2):138-40. PubMed ID: 25997310
    [No Abstract]   [Full Text] [Related]  

  • 5. Paradoxical decrease in serum high-density lipoprotein cholesterol and lipid-lowering drugs.
    Crook MA
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):3-4. PubMed ID: 21273636
    [No Abstract]   [Full Text] [Related]  

  • 6. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2004 Jun; 93(11):1417-8, A9. PubMed ID: 15165929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
    Waters DD; Ho JE; Boekholdt SM; DeMicco DA; Kastelein JJ; Messig M; Breazna A; Pedersen TR
    J Am Coll Cardiol; 2013 Jan; 61(2):148-52. PubMed ID: 23219296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
    Paradis JM; LeLorier J
    N Engl J Med; 2004 Aug; 351(7):714-7; author reply 714-7. PubMed ID: 15309744
    [No Abstract]   [Full Text] [Related]  

  • 9. How to balance cardiometabolic benefits and risks of statins.
    Koh KK
    J Am Coll Cardiol; 2013 May; 61(18):1932-3. PubMed ID: 23500235
    [No Abstract]   [Full Text] [Related]  

  • 10. Intensive lipid lowering with atorvastatin in coronary disease.
    Ravnskov U; Rosch PJ; Sutter MC
    N Engl J Med; 2005 Jul; 353(1):93-6; author reply 93-6. PubMed ID: 16003834
    [No Abstract]   [Full Text] [Related]  

  • 11. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P;
    Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply: To PMID 23219296.
    Waters DD; Boekholdt SM; Pedersen TR
    J Am Coll Cardiol; 2013 May; 61(18):1934. PubMed ID: 23500266
    [No Abstract]   [Full Text] [Related]  

  • 13. Statin treatment and diabetes.
    Kennedy RL; Vangaveti V; Malabu UH
    J Am Coll Cardiol; 2013 May; 61(18):1933-4. PubMed ID: 23500211
    [No Abstract]   [Full Text] [Related]  

  • 14. Discontinuation of statin therapy due to muscular side effects: a survey in real life.
    Rosenbaum D; Dallongeville J; Sabouret P; Bruckert E
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):871-5. PubMed ID: 22748604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin-associated rhabdomyolysis: is there a dose-response relationship?
    Holbrook A; Wright M; Sung M; Ribic C; Baker S
    Can J Cardiol; 2011; 27(2):146-51. PubMed ID: 21459261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin.
    Hsyu PH; Schultz-Smith MD; Lillibridge JH; Lewis RH; Kerr BM
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3445-50. PubMed ID: 11709322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
    Ramachandran S; Saraf S; Shetty C; Capps N; Bailey C
    Ann Clin Biochem; 2011 Jan; 48(Pt 1):75-8. PubMed ID: 21115572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholesterol level goal attainment with statins: clinical management guideline recommendations versus management in actual clinical practice.
    Heintjes EM; Penning-van Beest FJ; Plat AW; Meerding WJ; Webb K; Sturkenboom MC; Herings RM
    Pharmacotherapy; 2012 Jul; 32(7):631-41. PubMed ID: 22760692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of high-dose atorvastatin therapy.
    Waters DD
    Am J Cardiol; 2005 Sep; 96(5A):69F-75F. PubMed ID: 16126026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statin wars: efficacy vs. cost.
    Wierzbicki AS
    Int J Clin Pract; 2011 Feb; 65(2):108-11. PubMed ID: 21235691
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.